Clinical Trial Results: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 substudy evaluating pembrolizumab in combination with investigational agents for PD-1 refractory melanoma; results completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-08-13